Comparing diabetes drugs - Helping clinical decisions?

The Lancet

Volumn 381, Issue 9861, 2013, Pages 93-94

  Thethi, Tina ^a   Fonseca, Vivian ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ADVERSE OUTCOME; ANTIBODY TITER; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; STUDY DESIGN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84872058024     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61576-1     Document Type: Note

References (11)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes. Diabetes Care 2012; 35: 1364-79.
2. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-54.
3. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2012; published online Nov 7. http://dx.doi.org/10.1016/S0140-6736(12)61267-7.
4. Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012; 14: 77-82.
5. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open label, non-inferiority study. Lancet 2008; 372: 1240-50.
6. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-10.
7. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 2011; 27: 528-42.
8. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011; 96: 1695-702.
9. Buse JB, Rosenstock J, Sesti G, et al, for the LEAD-6 study group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
10. Buse JB, Sesti G, Schmidt WE, et al, for the Liraglutide Effect Action in Diabetes-6 study group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33: 1300-03.
11. Fineman MS, Mace KF, Diamant M, Darsow T, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14: 546-54.